# Actinogen Medical Closes Quarter With A$21.9 Million and XanaMIA Readout Due in November

> Actinogen Medical ended September with A$21.9 million in pro-forma cash and its XanaMIA Alzheimer's trial on track for November topline results.

- Published: 2026-10-19T04:00:27+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-19/actinogen-medical-xanamem-xanamiai-quarter
- Source: [EIN Presswire](https://www.einnews.com/article/950625291/live)

## Key takeaways

- Actinogen Medical reported a pro-forma cash position of about A$21.9 million after the September quarter.
- The XanaMIA Phase 2b/3 trial of Xanamem 10 mg once daily is on track for topline results in November.
- Eighty-seven percent of eligible participants moved into the open-label extension, where around 160 patients receive active Xanamem.

[Actinogen Medical](https://akta.pro/company-profiles/0007uc4/actinogen-medical) closed the September quarter with its XanaMIA Phase 2b/3 Alzheimer's disease trial on track for topline results in November and a pro-forma cash position of about A$21.9 million, [EIN Presswire](https://www.einnews.com/article/950625291/live) reported. The company said the final patient visit was completed in late September.

## XanaMIA Trial Reaches Final Patient Visit

Actinogen Medical is a Sydney-based clinical-stage company developing Xanamem, an oral once-daily therapy targeting brain cortisol, according to akta.pro [company records](https://akta.pro/company-data). The XanaMIA trial is evaluating Xanamem 10 mg once daily in patients with mild to moderate Alzheimer's disease, with the Clinical Dementia Rating Scale Sum of Boxes as the primary endpoint.

Treatment and follow-up progressed as planned across participating clinical sites in Australia and the US, and the company is now focused on ensuring the clinical database is complete and ready for analysis ahead of the November topline announcement. Actinogen is also preparing regulatory, clinical development and partnering pathways that could support Xanamem moving into a final pivotal Alzheimer's trial if the November results are positive.

Participation in the XanaMIA open-label extension continued to build during the quarter, with 87% of eligible participants choosing to move directly into the extension and receive active Xanamem. Around 160 patients are now receiving Xanamem 10 mg once daily under the program, which allows treatment for up to 25 months without a placebo arm. The extension is designed to provide longer-term safety information while collecting observational data across key efficacy measures including cognition, activities of daily living and the Clinical Dementia Rating Scale Sum of Boxes.

## Cash Position and Quarterly Spending

Actinogen ended September with A$15.9 million in cash, supported by A$5.3 million received from the exercise and underwriting of unlisted options during the quarter. The company has also accrued an A$10.8 million research and development tax rebate, which is expected to deliver net proceeds of approximately A$6 million after repayment of funding advanced against the rebate, lifting its pro-forma cash position to about A$21.9 million. Operating expenditure for the quarter was A$6.2 million, with most of the spending directed towards XanaMIA and the open-label extension.

## Earlier Steps Toward the November Readout

In September 2026, Actinogen Medical secured $4.77 million in additional funding after Forrest Capital agreed to fully underwrite the exercise of its remaining unlisted options, Proactiveinvestors reported. In August 2026, the company hosted a webinar to discuss the future of Alzheimer's treatment as it approached the pivotal XanaMIA clinical trial readout expected in November 2026, Proactiveinvestors reported. In July 2026, Actinogen Medical announced that its fully enrolled Phase 2b/3 XanaMIA Alzheimer's disease trial remained on schedule for topline results in November 2026, with an independent Data Monitoring Committee completing its third safety review and recommending the study continue without amendment, Yahoo reported.

## What Comes After the November Results

Actinogen expects its existing funding position to provide runway into late 2027 or potentially 2028, assuming future trials are substantially supported through partnerships. A further A$22.5 million could potentially be received from listed option exercises during 2027. The company said it intends to progress regulatory engagement and preparations for a final pivotal Alzheimer's disease trial if the study is positive, most likely in partnership with one or more development partners.

## Companies in this story

- [Actinogen Medical company profile](https://akta.pro/company-profiles/0007uc4/actinogen-medical) · website: https://actinogen.com.au

---
News for Agent · https://newsforagent.com/llms.txt